证券代码：000985 证券简称：大庆华科 公告编号：2025039 大庆华科股份有限公司 2025年第二次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东会没有出现否决提案的情形。 2、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 （1）现场会议召开时间：2025年9月26日（星期五）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票 的 具 体 时 间 为 ： 2025 年 9 月 26 日 9:15—9:25 ， 9:30—11:30 和 13:00—15:00。 通过深圳证券交易所互联网投票系统进行网络投票的具体时间为： 2025年9月26日9:15--15:00。 2、会议召开地点：大庆市龙凤区兴化北街8号公司办公楼一楼会议 室。 3、召开方式：现场投票与网络投票相结合的方式。 （2）中小股东出席会议的总体情况 通过现场和网络投票的股东36人，代表股份232,200股，占公司有 表决权股份总数129,639,500股的0.1791%。 4、召 ...

编号：黑司律见字【2025】0926-1 号 大庆华科股份有限公司 二〇二五年第二次临时股东会 法 律 意 见 书 黑龙江司洋律师事务所 二〇二五年九月二十六日 大庆华科 2025 年第二次临时股东会 司洋 法律意见书 黑龙江司洋律师事务所 关于大庆华科股份有限公司 2025 年第二次临时股东会 法律意见书 致：大庆华科股份有限公司 根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人 民共和国公司法》（以下简称《公司法》）和中国证券监督管理委员会《上 市公司股东会规则》（以下简称《股东会规则》）等法律、行政法规、规 范性文件及《大庆华科股份有限公司章程》（以下简称《公司章程》）的 要求，黑龙江司洋律师事务所（以下简称本所）接受大庆华科股份有限公 司（以下简称公司）的委托，指派律师出席公司 2025 年第二次临时股东会 （以下简称本次股东会）。 本所声明：本所律师仅对本次股东会的召集程序、召开程序、出席会 议人员资格、召集人资格、表决程序、表决结果及会议决议发表法律意见， 并不对本次股东会所审议的议案、议案所涉及的数字及内容发表意见。本 所律师同意将本法律意见书随本次股东会其他信息披露资料一并公告。 ...

Meeting Information - The company will hold its second extraordinary general meeting of shareholders for 2025 on September 26, 2025, at 14:30 [1] - The meeting will be conducted in a combination of on-site voting and online voting [3] - The record date for shareholders to attend the meeting is September 19, 2025 [4] Voting Details - On-site voting will take place on September 26, 2025, from 14:30, while online voting through the Shenzhen Stock Exchange trading system will be available from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 [2][20] - Shareholders can also vote via the internet from 9:15 to 15:00 on the same day [20] Attendance and Registration - Shareholders or their agents holding shares as of the record date are entitled to attend the meeting [4] - Registration for corporate shareholders requires specific documentation, while individual shareholders must present their ID and proof of shareholding [11][12] Agenda and Proposals - The meeting will review proposals that have been approved by the company's board of directors [9] - One of the proposals requires a special resolution, needing more than two-thirds of the voting rights held by attending shareholders to pass [10] Contact Information - The company has provided contact details for inquiries related to the meeting [18]

关于召开 2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 大庆华科股份有限公司（以下简称"公司"）定于 2025 年 9 月 26 日（星期五）14:30 召开 2025 年第二次临时股东会（以下简称"本 次股东会"）。会议通知公告（公告编号 2025037）已于 2025 年 9 月 10 日在巨潮资讯网(http://www.cninfo.com.cn) 、《中国证券报》 及《上海证券报》上发布。本次股东会将采用现场投票和网络投票相 结合的方式，现对公司召开本次股东会再次提示公告如下： 一、召开会议的基本情况 证券代码：000985 证券简称：大庆华科 公告编号：2025038 大庆华科股份有限公司 1、股东会届次:2025 年第二次临时股东会。 2、股东会的召集人:公司董事会。 3、会议召开的合法、合规性:本次会议召开符合公司法、证券法 及公司章程等法律、法规、部门规章、规范性文件及业务规则的相关 规定。 4、会议召开时间 （1）现场会议：2025 年 9 月 26 日（星期五）14:30 （2）网络投票 通过深圳证 ...

Group 1 - The company held a performance briefing on September 16, 2025, to discuss its operating results and financial indicators for the first half of 2025 [1] - Daqing Huake primarily engages in the production and sales of petrochemical products, including C9 and C5 series resins and polypropylene powder, with applications in various industrial sectors [1] - In the first half of 2025, the company achieved operating revenue of 959 million yuan, a year-on-year decrease of 0.85%, and a net profit of 9.064 million yuan, a year-on-year increase of 12.99% [1] Group 2 - The company utilizes by-products from ethylene cracking, such as C5 and propylene, for downstream processing, focusing on enhancing and extending its industrial chain [2] - In 2024, the company invested in a 10,800-ton/year butadiene extraction facility, which has been put into operation, and in 2025, it expanded its isoprene hydrogenation facility to 35,000 tons/year [2] - The company aims to strengthen its core competitiveness by collaborating with research institutions and industry leaders, promoting a new model of "industry-university-research-application" cooperation [2] Group 3 - The company previously announced the unsuccessful public listing of its pharmaceutical division's machinery assets, initially priced at 11.8351 million yuan, which was later reduced to 10.6516 million yuan without finding a buyer [3] - The company will continue to seek potential buyers for the assets of its pharmaceutical division following two unsuccessful attempts at public transfer [3]

Core Viewpoint - Daqing Huake's performance in the first half of 2025 shows a slight decline in revenue but an increase in net profit, indicating resilience in a challenging market environment [1][2]. Group 1: Financial Performance - In the first half of 2025, Daqing Huake achieved operating revenue of 959 million yuan, a year-on-year decrease of 0.85% [1]. - The company reported a net profit of 9.064 million yuan, reflecting a year-on-year increase of 12.99% [1]. - The non-recurring net profit was 7.9774 million yuan, which represents a year-on-year decrease of 8.5% [1]. Group 2: Business Operations and Strategy - Daqing Huake primarily engages in the production and sales of petrochemical products, including C5 and C9 series resins and polypropylene powder, with applications in various industrial sectors [1][2]. - The company has invested in expanding its production capabilities, including a 10,800-ton/year butadiene extraction facility and a capacity expansion project for isoprene hydrogenation, now at 35,000 tons/year [2]. - Daqing Huake aims to enhance its C5/C9/propylene industrial chains, focusing on functional, specialized, and high-end applications, while fostering collaborations with research institutions and industry leaders [2]. Group 3: Asset Management - Daqing Huake attempted to sell machinery assets from its pharmaceutical division, initially listed at an assessed value of 11.8351 million yuan, but failed to attract buyers [3]. - The company reduced the asking price to 10.6516 million yuan in a second attempt, which also did not yield any interested parties, leading to the termination of the sale process [3].

Group 1: Investor Relations Activities - The investor relations activity was conducted via an online platform on September 12, 2025, from 15:00 to 16:00 [2] - Key participants included the Chairwoman Zhang Caihong, General Manager Dou Yan, and Financial Director Wu Yunfeng [2] - The company addressed various investor questions during the earnings briefing [2] Group 2: Product Development and R&D - The planning project department has established a dedicated R&D team of 6 personnel, focusing on the "Polypropylene Plant Liquid Catalyst Injection System Process Development" project [2] - The project aims to optimize product structure and enhance product variety through research on polymerization processes and catalyst dosage [2] Group 3: Production Capacity and Utilization - The company is currently operating all major production facilities as planned, with specific capacity utilization rates to be disclosed in regular reports [3][4] - The isobutylene hydrogenation unit has been expanded to a capacity of 35,000 tons/year [5] Group 4: Financial Performance and Growth Strategy - The company aims to enhance its core competitiveness by improving the C5/C9/propylene industrial chain and transitioning products towards functional, specialized, and high-end applications [3] - In 2024, the company invested in a 10,800 tons/year butadiene extraction unit, which has already been put into production [5] - The company is exploring new business areas to mitigate risks associated with its 100% revenue reliance on the chemical business [5] Group 5: Asset Management - The pharmaceutical division's assets were unsuccessfully listed for sale in 2017 and 2025, with plans to seek potential buyers in the future [6]

Group 1 - Daqing Huake Co., Ltd. announced the procurement of petroleum resin packaging bags on September 10, 2025 [1] - The company has made investments in one enterprise and participated in 828 bidding projects [1] - Daqing Huake holds 7 trademark registrations and 11 patents, along with 201 administrative licenses [1] Group 2 - The supplier for the procurement is Liaoning Hongfeng Packaging Co., Ltd. [2] - The procurement is located in Heilongjiang Province [2]

Core Viewpoint - Daqing Huake announced the appointment of Lixin Certified Public Accountants as the auditing firm for the financial report and internal control for the year 2025 [2] Group 1 - The company intends to enhance its financial reporting and internal control processes by engaging a reputable auditing firm [2]

Core Viewpoint - Daqing Huake (000985) announced the election of Ms. Cui Fengling as the employee director of the company's ninth board of directors during a recent employee representative meeting [1] Group 1 - The company held an employee representative meeting to facilitate the election process [1] - Ms. Cui Fengling was elected as the employee director, indicating a move towards employee representation in the board [1]